Trends in Anticoagulant Use at Nursing Home Admission and Variation by Frailty and Chronic Kidney Disease Among Older Adults with Atrial Fibrillation.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
02
04
2021
pubmed:
22
4
2021
medline:
25
2
2023
entrez:
21
4
2021
Statut:
ppublish
Résumé
Atrial fibrillation (AF) is relatively common among nursing home residents, and decisions regarding anticoagulant therapy in this setting may be complicated by resident frailty and other factors. The aim of this study was to examine trends and correlates of oral anticoagulant use among newly admitted nursing home residents with AF following the approval of direct-acting oral anticoagulants (DOACs). We conducted a retrospective cohort study of all adults aged > 65 years with AF who were newly admitted to nursing homes in Ontario, Canada, between 2011 and 2018 (N = 36,466). Health administrative databases were linked with comprehensive clinical assessment data captured shortly after admission, to ascertain resident characteristics. Trends in prevalence of anticoagulant use (any, warfarin, DOAC) at admission were captured with prescription claims and examined by frailty and chronic kidney disease (CKD). Log-binomial regression models estimated crude percentage changes in use over time and modified Poisson regression models assessed factors associated with anticoagulant use and type. The prevalence of anticoagulant use at admission increased from 41.1% in 2011/2012 to 58.0% in 2017/2018 (percentage increase = 41.1%, p < 0.001). Warfarin use declined (- 67.7%, p < 0.001), while DOAC use increased. Anticoagulant use was less likely among residents with a prior hospitalization for hemorrhagic stroke (adjusted risk ratio [aRR] 0.65, 95% confidence interval [CI] 0.60-0.70) or gastrointestinal bleed (aRR 0.80, 95% CI 0.78-0.83), liver disease (aRR 0.78, 95% CI 0.69-0.89), severe cognitive impairment (aRR 0.89, 95% CI 0.85-0.94), and non-steroidal anti-inflammatory drug (aRR 0.76, 95% CI 0.71-0.81) or antiplatelet (aRR 0.25, 95% CI 0.23-0.27) use, but more likely for those with a prior hospitalization for ischemic stroke or thromboembolism (aRR 1.30, 95% CI 1.27-1.33). CKD was associated with a reduced likelihood of DOAC versus warfarin use in both the early (aRR 0.62, 95% CI 0.54-0.71) and later years (aRR 0.79, 95% CI 0.76-0.83) of our study period. Frail residents were significantly less likely to receive an anticoagulant at admission, although this association was modest (aRR 0.95, 95% CI 0.92-0.98). Frailty was not associated with anticoagulant type. While the proportion of residents with AF receiving oral anticoagulants at admission increased following the approval of DOACs, over 40% remained untreated. Among those treated, use of a DOAC increased, while warfarin use declined. The impact of these recent treatment patterns on the balance between benefit and harm among residents warrant further investigation.
Sections du résumé
BACKGROUND
Atrial fibrillation (AF) is relatively common among nursing home residents, and decisions regarding anticoagulant therapy in this setting may be complicated by resident frailty and other factors.
OBJECTIVES
The aim of this study was to examine trends and correlates of oral anticoagulant use among newly admitted nursing home residents with AF following the approval of direct-acting oral anticoagulants (DOACs).
METHODS
We conducted a retrospective cohort study of all adults aged > 65 years with AF who were newly admitted to nursing homes in Ontario, Canada, between 2011 and 2018 (N = 36,466). Health administrative databases were linked with comprehensive clinical assessment data captured shortly after admission, to ascertain resident characteristics. Trends in prevalence of anticoagulant use (any, warfarin, DOAC) at admission were captured with prescription claims and examined by frailty and chronic kidney disease (CKD). Log-binomial regression models estimated crude percentage changes in use over time and modified Poisson regression models assessed factors associated with anticoagulant use and type.
RESULTS
The prevalence of anticoagulant use at admission increased from 41.1% in 2011/2012 to 58.0% in 2017/2018 (percentage increase = 41.1%, p < 0.001). Warfarin use declined (- 67.7%, p < 0.001), while DOAC use increased. Anticoagulant use was less likely among residents with a prior hospitalization for hemorrhagic stroke (adjusted risk ratio [aRR] 0.65, 95% confidence interval [CI] 0.60-0.70) or gastrointestinal bleed (aRR 0.80, 95% CI 0.78-0.83), liver disease (aRR 0.78, 95% CI 0.69-0.89), severe cognitive impairment (aRR 0.89, 95% CI 0.85-0.94), and non-steroidal anti-inflammatory drug (aRR 0.76, 95% CI 0.71-0.81) or antiplatelet (aRR 0.25, 95% CI 0.23-0.27) use, but more likely for those with a prior hospitalization for ischemic stroke or thromboembolism (aRR 1.30, 95% CI 1.27-1.33). CKD was associated with a reduced likelihood of DOAC versus warfarin use in both the early (aRR 0.62, 95% CI 0.54-0.71) and later years (aRR 0.79, 95% CI 0.76-0.83) of our study period. Frail residents were significantly less likely to receive an anticoagulant at admission, although this association was modest (aRR 0.95, 95% CI 0.92-0.98). Frailty was not associated with anticoagulant type.
CONCLUSIONS
While the proportion of residents with AF receiving oral anticoagulants at admission increased following the approval of DOACs, over 40% remained untreated. Among those treated, use of a DOAC increased, while warfarin use declined. The impact of these recent treatment patterns on the balance between benefit and harm among residents warrant further investigation.
Identifiants
pubmed: 33880747
doi: 10.1007/s40266-021-00859-1
pii: 10.1007/s40266-021-00859-1
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
611-623Subventions
Organisme : CIHR
ID : MOP-136854
Pays : Canada
Références
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke. 1991;22(8):983–8.
doi: 10.1161/01.STR.22.8.983
Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115–9.
doi: 10.1161/01.STR.0000166053.83476.4a
Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke. 1996;27(10):1760–4.
doi: 10.1161/01.STR.27.10.1760
Andrade JG, Verma A, Mitchell LB, Parkash R, Leblanc K, Atzema C, et al. 2018 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol. 2018;34(11):1371–92.
doi: 10.1016/j.cjca.2018.08.026
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51.
doi: 10.1161/CIR.0000000000000665
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
doi: 10.7326/0003-4819-146-12-200706190-00007
Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300-5.e2.
doi: 10.1016/j.amjmed.2015.05.044
Gao L, Tadrous M, Knowles S, Mamdani M, Paterson JM, Juurlink D, et al. Prior authorization and canadian public utilization of direct-acting oral anticoagulants. Healthc Policy. 2017;13(2):68–78.
pubmed: 29274228
pmcid: 5749525
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA. 2001;285(18):2370–5.
doi: 10.1001/jama.285.18.2370
Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167(5):1807–24.
doi: 10.1016/j.ijcard.2012.12.093
Alcusky M, Lapane KL. Treatment of atrial fibrillation in nursing homes: a place for direct acting oral anticoagulants? J Nurs Home Res Sci. 2018;4:15–9.
pubmed: 31549021
pmcid: 6756768
Reardon G, Nelson WW, Patel AA, Philpot T, Neidecker M. Prevalence of atrial fibrillation in us nursing homes: results from the national nursing home survey, 1985–2004. J Am Med Dir Assoc. 2012;13(6):529–34.
doi: 10.1016/j.jamda.2012.03.007
Maclagan LC, Bronskill SE, Guan J, Campitelli MA, Herrmann N, Lapane KL, et al. Predictors of cholinesterase discontinuation during the first year after nursing home admission. J Am Med Dir Assoc. 2018;19(11):959-66 e4.
doi: 10.1016/j.jamda.2018.07.020
Alcusky M, McManus DD, Hume AL, Fisher M, Tjia J, Lapane KL. Changes in anticoagulant utilization among United States nursing home residents with atrial fibrillation from 2011 to 2016. J Am Heart Assoc. 2019;8(9):e012023.
doi: 10.1161/JAHA.119.012023
Maclagan LC, Maxwell CJ, Gandhi S, Guan J, Bell CM, Hogan DB, et al. Frailty and potentially inappropriate medication use at nursing home transition. J Am Geriatr Soc. 2017;65(10):2205–12.
doi: 10.1111/jgs.15016
Campitelli MA, Maxwell CJ, Giannakeas V, Bell CM, Daneman N, Jeffs L, et al. The variation of statin use among nursing home residents and physicians: a cross-sectional analysis. J Am Geriatr Soc. 2017;65(9):2044–51.
doi: 10.1111/jgs.15013
Daneman N, Campitelli MA, Giannakeas V, Morris AM, Bell CM, Maxwell CJ, et al. Influences on the start, selection and duration of treatment with antibiotics in long-term care facilities. CMAJ. 2017;189(25):E851–60.
doi: 10.1503/cmaj.161437
Tu K, Nieuwlaat R, Cheng SY, Wing L, Ivers N, Atzema CL, et al. Identifying patients with atrial fibrillation in administrative data. Can J Cardiol. 2016;32(12):1561–5.
doi: 10.1016/j.cjca.2016.06.006
Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7(8):e008643.
doi: 10.1161/JAHA.118.008643
Campitelli MA, Bronskill SE, Hogan DB, Diong C, Amuah JE, Gill S, et al. The prevalence and health consequences of frailty in a population-based older home care cohort: a comparison of different measures. BMC Geriatr. 2016;16:133.
doi: 10.1186/s12877-016-0309-z
Fleet JL, Dixon SN, Shariff SZ, Quinn RR, Nash DM, Harel Z, et al. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol. 2013;14:81.
doi: 10.1186/1471-2369-14-81
Morris JN, Fries BE, Mehr DR, Hawes C, Phillips C, Mor V, et al. Mds cognitive performance scale. J Gerontol. 1994;49(4):M174–82.
doi: 10.1093/geronj/49.4.M174
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.
doi: 10.1378/chest.09-1584
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107.
doi: 10.1002/sim.3697
Zou GY, Donner A. Extension of the modified poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2013;22(6):661–70.
doi: 10.1177/0962280211427759
Reardon G, Nelson WW, Patel AA, Philpot T, Neidecker M. Warfarin for prevention of thrombosis among long-term care residents with atrial fibrillation: evidence of continuing low use despite consideration of stroke and bleeding risk. Drugs Aging. 2013;30(6):417–28.
doi: 10.1007/s40266-013-0067-y
Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot JM, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–6.
doi: 10.1111/jgs.13200
Jobski K, Hoffmann F, Herget-Rosenthal S, Dorks M. Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice. Br J Clin Pharmacol. 2018;84(3):590–601.
doi: 10.1111/bcp.13474
Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774–82.
doi: 10.1002/clc.23196
Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, et al. Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72(3):255–67.
doi: 10.1016/j.jacc.2018.04.063
Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (re-ly) trial. Circulation. 2013;127(5):634–40.
doi: 10.1161/CIRCULATIONAHA.112.115386
Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing. 2011;40(6):675–83.
doi: 10.1093/ageing/afr097
Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother. 2008;42(4):523–32.
doi: 10.1345/aph.1K498
O’Neal WT, Sandesara PB, Claxton JS, MacLehose RF, Chen LY, Bengtson LGS, et al. Influence of sociodemographic factors and provider specialty on anticoagulation prescription fill patterns and outcomes in atrial fibrillation. Am J Cardiol. 2018;122(3):388–94.
doi: 10.1016/j.amjcard.2018.04.022
Lefebvre MC, St-Onge M, Glazer-Cavanagh M, Bell L, Kha Nguyen JN, Viet-Quoc Nguyen P, et al. The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can J Cardiol. 2016;32(2):169–76.
doi: 10.1016/j.cjca.2015.05.012
Wilkinson C, Todd O, Clegg A, Gale CP, Hall M. Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis. Age Ageing. 2019;48(2):196–203.
doi: 10.1093/ageing/afy180
Villani ER, Tummolo AM, Palmer K, Gravina EM, Vetrano DL, Bernabei R, et al. Frailty and atrial fibrillation: a systematic review. Eur J Intern Med. 2018;56:33–8.
doi: 10.1016/j.ejim.2018.04.018
Hogan DB, Maxwell CJ. Frailty and unintended risks of medications. Curr Epidemiol Rep. 2020;7(1):16–24.
doi: 10.1007/s40471-020-00226-5
O’Neal WT, Sandesara PB, Claxton JS, MacLehose RF, Chen LY, Bengtson LGS, et al. Provider specialty, anticoagulation prescription patterns, and stroke risk in atrial fibrillation. J Am Heart Assoc. 2018;7(6):e007943.
doi: 10.1161/JAHA.117.007943
Alcusky M, Tjia J, McManus DD, Hume AL, Fisher M, Lapane KL. Comparative safety and effectiveness of direct-acting oral anticoagulants versus warfarin: a national cohort study of nursing home residents. J Gen Intern Med. 2020;35(8):2329–37.
doi: 10.1007/s11606-020-05777-3